Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alfasigma S.p.A.

http://www.alfasigma.com/en

Latest From Alfasigma S.p.A.

Vifor Clinches Deal For Travere's Rare Kidney Disorder Drug

The Swiss group has delivered on its promise to secure more deals in the nephrology space by bagging the rights in Europe, Australia and New Zealand to sparsentan, which is deep into a Phase III program for focal segmental glomerulosclerosis and IgA nephropathy.

Renal Deals

Delay For Calliditas Kidney Drug Not Major Cause For Concern

Shares in Sweden's Calliditas have taken a tumble on the news that the US FDA has pushed back the action date for its immunoglobulin A nephropathy Nefecon. However, the company, and certain analysts, are less worried, believing the delay is just a blip.

Drug Review Renal

Deal Watch: Visus Begins Charting Its Direction In Ophthalmology With Two Deals

Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.

Deal Watch Business Strategies

Travere Positioned To Seek Accelerated Approval In Rare Kidney Disorder

With interim Phase III data showing threefold reduction in proteinuria reduction compared to SOC, Travere plans to seek accelerated US and EU approval of sparsentan in immunoglobulin A nephropathy.

Clinical Trials Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • ALFASIGMA
    • Defiante Farmaceutica S.A.
    • Sigma-Tau Pharma Ltd
    • Sigma-Tau Arzneimittel GmbH
    • Sigma-Tau Research Switzerland SA
    • Biofutura Pharma S.p.A.
    • Alfa Wassermann SpA
UsernamePublicRestriction

Register